Candel Therapeutics Hosts a Virtual R&D Event
Candel Therapeutics, Inc. (Candel), a leading clinical-stage biopharmaceutical company specializing in cancer treatments, is excited to host a virtual Research and Development (R&D) event. This online gathering is scheduled from 11:00 am to 1:45 pm ET, promising insightful presentations and discussions about the company's innovative approach to transforming cancer care.
Overview of the R&D Day
The event will showcase a variety of presentations from Candel's executive team, clinical investigators, and significant scientific advisors. Attendees can expect an in-depth exploration of Candel's unique viral immunotherapy strategies and an overview of their oncology-focused product pipeline. This is an excellent opportunity for individuals interested in the latest advancements in immunotherapy.
Highlighting Key Presentations
Among the key presentations, Candel’s President and CEO, Paul Peter Tak, MD, PhD, will offer an introduction to the company and its mission. The R&D Day will also feature a panel discussion titled "Immuno-oncology: The Next Wave of Innovation," including leading experts in the field. Esteemed panelists consist of Nobel Laureate James P. Allison, MD, and renowned medical experts such as Carl H. June, MD, and Padmanee Sharma, MD, PhD.
Deep Dive into CAN-2409
One significant focus will be on CAN-2409, Candel's leading multimodal biological immunotherapy candidate. The presentation will explore how CAN-2409 is developed to treat various types of solid tumors by inducing a personalized systemic immune response through innovative mechanisms. The potential of this candidate in conjunction with standard treatments has shown promising results in previous clinical studies.
Exploring Future Pathways with CAN-3110
Another critical topic will be CAN-3110, a next-generation oncolytic viral immunotherapy candidate currently in clinical trials. As a pioneering therapy utilizing herpes simplex virus-1, CAN-3110 aims to stimulate an immune response to combat cancer. Early reports suggest it is well-tolerated and offers potential therapeutic advantages.
Registration and Access Information
Those interested in learning more and participating in the event can register on Candel's official website. All registered individuals will have access to live webcasts and subsequent replays, ensuring that valuable insights shared during the R&D Day can be revisited at participants' convenience.
About Candel Therapeutics
Candel Therapeutics is dedicated to developing breakthrough multimodal biological immunotherapies that act against cancer. The company has successfully initiated multiple clinical trials to validate the efficacy of its product candidates, CAN-2409 and CAN-3110. With its innovative platforms, Candel aims to leverage the immune system's capabilities to foster targeted and robust responses to cancer treatment.
For ongoing updates and more information about Candel and its promising therapies, individuals are encouraged to visit the company's website.
Frequently Asked Questions
What is the purpose of the Candel R&D Day?
The R&D Day aims to showcase Candel's innovative cancer therapies and provide insights into their immunotherapy approach.
Who are the key presenters at the event?
Notable presenters include Candel's President, Paul Peter Tak, MD, and several leading experts in immunology and oncology, including James P. Allison, MD.
What is CAN-2409?
CAN-2409 is Candel's leading investigational therapy designed for delivering cancer treatment by inducing an immune response through specific mechanisms.
How can I register for the event?
Registration is available on Candel's official website, where attendees can sign up to access the live event and replays.
What is the significance of CAN-3110?
CAN-3110 is a next-generation oncolytic virus candidate that has shown potential in treating therapy-resistant cancer through immune activation.
